TARS

Tarsus Pharmaceuticals Inc

TARS.US tarsusrx.com
79.31
-1.81 (-2.23%)
USD · NASDAQ
52-week range
48.20
91.53
Trading at 72% of the 52-week range
Market Cap
3.71B
P/E Ratio
0.00
Forward P/E
72.99
Book Value
8.01
Div. Yield
N/A
% Institutions
106.03%
% Insiders
2.86%

1 Year

+52.9%

3 Year

+382.7%

10 Year

+285.4%
Description

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Company Information

Company Name
Tarsus Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US87650L1035
CIK: 0001819790
CUSIP: 87650L103
Currency: USD
Full Time Employees: 370
Phone: 949 418 1801
Fiscal Year End: December
IPO Date: Oct 16, 2020
Description:

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Address:

17700 Laguna Canyon Road, Irvine, CA, United States, 92618

People

Directors & Officers

Name Title Year Born
Dr. Bobak R. Azamian M.D. Co-Founder, President, CEO & Chairman NA
Mr. Jeffrey S. Farrow CPA CFO & Chief Strategy Officer 1962
Dr. Seshadri Neervannan Ph.D. Chief Operating Officer 1968
Dr. Bryan Wahl J.D., M.D. General Counsel & Corporate Secretary 1978
Mr. David Nakasone Head of Investor Relations NA
Ms. Adrienne Kemp Vice President of Corporate Communications NA
Mr. Matthew Rossen M.B.A. Vice President of Marketing 1978
Mr. Scott Youmans Vice President of Sales NA
Ms. Dianne C. Whitfield M.S.W. Chief Human Resources Officer 1977
Dr. Elizabeth Yeu-Lin M.D. Chief Medical Officer 1978

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Mar 19, 2026 Bryan Wahl N/A Sale 4.23K $67.00 $283.48K
Mar 19, 2026 Dianne C Whitfield N/A Sale 4.17K $67.00 $279.66K
Mar 19, 2026 Elizabeth Yeu Lin N/A Sale 390.00 $67.00 $26.13K
Mar 19, 2026 Jeffrey S Farrow N/A Sale 2.19K $67.00 $146.46K
Mar 19, 2026 Bobak R Azamian N/A Sale 11.96K $67.00 $801.59K
Mar 18, 2026 Bobak R Azamian N/A Sale 11.67K $68.71 $801.64K
Mar 18, 2026 Bryan Wahl N/A Sale 4.13K $68.71 $283.43K
Mar 18, 2026 Dianne C Whitfield N/A Sale 4.07K $68.71 $279.72K
Mar 18, 2026 Elizabeth Yeu Lin N/A Sale 379.00 $68.71 $26.04K
Mar 18, 2026 Jeffrey S Farrow N/A Sale 2.13K $68.71 $146.56K
Mar 17, 2026 Bobak R Azamian N/A Sale 10.97K $69.42 $761.68K
Mar 17, 2026 Jeffrey S Farrow N/A Sale 2.11K $69.42 $146.55K
Mar 17, 2026 Elizabeth Yeu Lin N/A Sale 375.00 $69.42 $26.03K
Mar 17, 2026 Dianne C Whitfield N/A Sale 4.03K $69.42 $279.69K
Mar 17, 2026 Bryan Wahl N/A Sale 4.08K $69.42 $283.51K
Mar 16, 2026 William J Phd Link N/A Sale 12.50K $68.79 $859.88K
Dec 24, 2025 Bobak R Azamian N/A Sale 6.00K $82.51 $495.06K
Dec 16, 2025 Dianne C Whitfield N/A Sale 7.40K $80.10 $592.50K
Sep 24, 2025 Bobak R Azamian N/A Sale 6.00K $55.37 $332.22K
Sep 08, 2025 William J Phd Link N/A Sale 27.12K $57.00 $1.55M

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Deep Track Capital, LP 3.67M Jun 30, 2026 8.36% $3.36 1.85%
BlackRock Inc 3.55M Mar 31, 2026 8.10% $0.00 -6.28%
RTW INVESTMENTS, LLC 3.35M Mar 31, 2026 7.62% $2.34 0.32%
Paradigm Biocapital Advisors LP 2.78M Jun 30, 2026 6.33% $3.27 8.33%
HHG PLC 2.24M Mar 31, 2026 5.11% $0.08 16.09%
Morgan Stanley - Brokerage Accounts 1.94M Mar 31, 2026 4.43% $0.01 -4.73%
Vanguard Capital Management, LLC 1.76M Mar 31, 2026 4.01% $0.00 0.00%
Jennison Associates LLC 1.66M Jun 30, 2026 3.79% $0.06 -2.83%
Millennium Management LLC 1.43M Jun 30, 2026 3.25% $0.03 152.78%
Bank of America Corp 1.19M Mar 31, 2026 2.72% $0.01 57.55%
TANG CAPITAL MANAGEMENT LLC 1.19M Mar 31, 2026 2.71% $4.23 0.00%
Geode Capital Management, LLC 1.12M Mar 31, 2026 2.55% $0.00 18.29%
State Street Corp 978.21K Mar 31, 2026 2.23% $0.00 5.29%
Assenagon Asset Management SA 947.50K Jun 30, 2026 2.16% $0.07 -25.99%
Driehaus Capital Management LLC 926.13K Mar 31, 2026 2.11% $0.48 -21.01%
Lord, Abbett & Co LLC 842.31K Mar 31, 2026 1.92% $0.19 -1.56%
Amvescap Plc. 742.50K Mar 31, 2026 1.69% $0.01 -26.66%
FMR Inc 733.33K Mar 31, 2026 1.67% $0.00 13.32%
Frazier Life Sciences Management, L.P. 728.64K Mar 31, 2026 1.66% $1.32 0.00%
D. E. Shaw & Co LP 710.56K Jun 30, 2026 1.62% $0.02 -10.19%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard MStar Total Stk Mkt Idx Invest 1.30M 2.97% ▲ 0.46% Jul 31, 2026
2 iShares Russell 2000 ETF 1.07M 2.45% ▼ 0.57% Aug 31, 2026
3 Vanguard Institutional Extnd Mkt Idx Tr 456.16K 1.04% ▲ 0.17% Jul 31, 2026
4 Fidelity Small Cap Index 453.65K 1.03% ▲ 15.37% Jun 30, 2026
5 PGIM Jennison Small Company A 408.23K 0.93% ▲ 0.00% Jul 31, 2026
6 Jennison SMid Cap Core Equity 408.23K 0.93% ▼ 6.10% Jun 30, 2026
7 MEDICAL BioHealth EUR Acc 401.12K 0.91% ▲ 1.71% Jul 31, 2026
8 iShares Russell 2000 Growth ETF 392.17K 0.89% ▲ 0.00% Aug 31, 2026
9 Janus Henderson Global Life Sciences 354.30K 0.81% ▲ 19.26% Jun 30, 2026
10 Janus Global Life Science AUSD 346.76K 0.79% ▲ 25.92% Jun 30, 2026

Financial Highlights

Market Cap: $3.71B
EBITDA: $-46.20M
Book Value: $8.01
Earnings/Share: $-1.07
Profit Margin: -7.67%
Operating Margin: -11.45%
ROA (TTM): -5.49%
ROE (TTM): -13.68%
Revenue (TTM): $606.33M
Revenue/Share (TTM): $14.12
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 69.40%

Valuation Metrics

Enterprise Value: $3.33B
Trailing P/E: 0.00
Forward P/E: 72.99

Shares Statistics

Shares Outstanding: 46.79M
Shares Float: 32.70M
% Insiders: 2.86%
% Institutions: 106.03%
Short % Float: 14.15%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$451.36M
Cost of Goods Sold
adjust
$-30.68M
Gross Profit
subtotal
$420.68M
SG&A
adjust
$-427.32M
R&D
adjust
$-64.32M
Operating Income
subtotal
$-70.97M
Other / Non-Operating Items
adjust
$4.55M
Net Income
subtotal
$-66.42M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about TARS.US!